• Target disease: Visceral leishmaniasis (VL)
  • Main Partners (since project start): Celgene Corporation, USA; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene & Tropical Medicine, UK; Sandexis, UK; WuXi AppTech, China.
  • Project start: 2015
  • Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International.


Overall Objective: 

  • Select a pre‑clinical candidate from the CGH VL series for the treatment of VL


A novel series of heterocyclic compounds for VL has been optimized by Celgene in collaboration with London School of Hygiene & Tropical Medicine and Advinus, and with advice from DNDi.


DNDi’s collaboration with Celgene Global Health continues to explore the potential of this series to deliver a pre-clinical candidate. Compounds with much improved physical properties, including improved aqueous solubility, were identified in 2017.

An in vivo proof-of-concept has been achieved for this series. An intensive lead optimization programme is ongoing with Celgene to identify an optimized lead. 


Last update: August 2018